Blueprint Medicines CORP Schedule 13G passive stakes

Pentwater Capital Management LP and Matthew Halbower have disclosed a 6.0% beneficial ownership stake in Blueprint Medicines Corp., totaling 3.9 million shares.

T. Rowe Price Associates, Inc. has filed an Amendment No. 9 to Schedule 13G, reporting a 2.3% beneficial ownership in Blueprint Medicines Corp.

Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 0.6% of Blueprint Medicines Corp's common stock.

Davidson Kempner Capital Management and its affiliates, including Anthony A. Yoseloff, have filed a Schedule 13G indicating they hold no beneficial ownership in Blueprint Medicines Corp as of July 14, 2025.

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 6.0% beneficial ownership stake in Blueprint Medicines Corp, holding 3,850,000 shares of common stock for investment purposes.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a 4.8% beneficial ownership stake in Blueprint Medicines Corporation as of March 31, 2025.

BlackRock, Inc. has disclosed an increased passive ownership stake of 8.0% in Blueprint Medicines Corp, holding over 5 million shares as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 3.5% beneficial ownership stake in Blueprint Medicines Corp. as of December 31, 2024.